Abstract
Protein kinase CK2 (CK2) is a ubiquitous serine/threonine protein kinase which serves as an attractive anticancer target. Herein we report new CK2 inhibitors with a 1,3-dioxo-2,3-dihydro-1H-indene core. Some derivatives showed much improved inhibitory activity on CK2, with an IC50 of 0.85 ± 0.09 μM for the best compound, SL-15. Our data provide a new scaffold for designing CK2 inhibitors and deserve further modifications.